Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements ...
The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback